ABSTRACT A 6-thioguanine-resistant, human lymphoblastoid B-cell line (GM1500 6TG A-ll; IgG secreting) was mutagentreated with low-level V-irradiation and selected for ouabain resistance. One line showing 10,000-fold higher drug resistance, designated KR4, was fused with an Epstein-Barr virus-transformed, cloned, B-lymphocyte cell line (B6) producing antitetanus toxoid (TT) antibody (IgM), and the hybrids were selected in hypoxanthine/aminopterin/thymidine medium containing 10 JIM ouabain. Surviving cells, which arose at an optimal frequency of i0-5, were subcloned by limiting dilution and screened for anti-TT production. Out of395 final subclones, 372 were found positive for anti-TT, and seven that were selected for further study secreted specific antibody (IgM, K chain) at a maximum concentration of 3-6 #g/ml. The differential rate of anti-TT production during the logarithmic phase of cell growth was 15-fold higher in the hybridomas than in the original B6 line. The hybrid nature of the clones was confirmed by karyotype analysis, histocompatibility antigen typing, and expression of secreted and membrane-bound Ig classes. Biosynthetic labeling of the cells revealed that all hybrids secreted both IgM and IgG but that only the IgM class had specificity for TT. Because Epstein-Barr virus is a polyclonal Blymphocyte activator, the technique we applied here may be useful for increasing the recovery of rare antigen-specific B cells in the peripheral blood and for improving the frequency and stability of hybridomas secreting a given antibody.
i0-5, were subcloned by limiting dilution and screened for anti-TT production. Out of395 final subclones, 372 were found positive for anti-TT, and seven that were selected for further study secreted specific antibody (IgM, K chain) at a maximum concentration of 3-6 #g/ml. The differential rate of anti-TT production during the logarithmic phase of cell growth was 15-fold higher in the hybridomas than in the original B6 line. The hybrid nature of the clones was confirmed by karyotype analysis, histocompatibility antigen typing, and expression of secreted and membrane-bound Ig classes. Biosynthetic labeling of the cells revealed that all hybrids secreted both IgM and IgG but that only the IgM class had specificity for TT. Because Epstein-Barr virus is a polyclonal Blymphocyte activator, the technique we applied here may be useful for increasing the recovery of rare antigen-specific B cells in the peripheral blood and for improving the frequency and stability of hybridomas secreting a given antibody.
The production of human monoclonal antibodies expressing a desired specificity has proved successful with methods that use either the lymphotropic Epstein-Barr virus (EBV) to immortalize antigen-specific B cells (1) (2) (3) (4) (5) or the classical hybridoma technique, whereby human blood lymphocytes are fused with murine (6) or human myeloma cell lines (7, 8) . To overcome difficulties inherent in each technique (9) , we examined the possibility of combining them. We have described a technique whereby lymphocytes from normal donors immunized with tetanus toxoid (TT) were preselected for antigen-binding cells, subsequently transformed with EBV, and cloned (10) . In the present study, an EBV-transformed clone B6 was fused with a human lymphoblastoid cell line ofthe B-cell type (B-LCL), KR-4, to rescue high amounts of anti-TT antibody production. The resulting hybridomas were found to be more stable, to have a higher cloning efficiency, and to secrete =8-fold more specific antibody compared with the parental B6 clone. In addition KR-4 had a 25-fold higher frequency of hybridization with EBVtransformed B cells compared with nontransformed B cells.
MATERIALS AND METHODS
Cell Lines. B6 is an anti-TT antibody-producing, EBV-transformed, cloned cell line that was previously established in our laboratory (10) . GM 1500 6TG A-li is a 6-thioguanine-resistant (SGuaR) [hypoxanthine/aminopterin/thymidine (HAT)-sensitive] human B-cell line, which was generously provided by H. Koprowski at The Wistar Institute in Philadelphia (8) . Both GM1500 and the KR-4 line that we derived were strongly positive for EBV nuclear antigen and both expressed surface-bound and cytoplasmic Igs as determined by immunofluorescence. Therefore, these lines are referred to as B-LCLs. Electron micrographs were consistent with this designation and revealed a less differentiated state than seen in myelomas.
Selection of an Ouabain-Resistant (OuaR) B-LCL. The human B-LCL GM1500 6TG A-l (106 cells per ml) was mutagentreated with either ethyl methanesulfonate (60-150 ,ug/ml; Sigma) for 24 hr, or with y-irradiation (100-300 R) (11) . After mutagenic treatment, cells were allowed a 10-day period of expression in normal medium and then were seeded (2 x 106 cells per ml) in 96-well microtiter plates (Linbro) in 0. 1-ml volumes in the presence of0.1 tM ouabain (Sigma). Cultures were fed every 4 days with ouabain-containing medium, and wells with viable colonies were scored after 2 wk. The surviving cells were then subcultured in 24-well tissue culture plates (Costar) and subsequently grown in flasks (Falcon) in gradually increasing concentrations ofouabain. Dead cells were removed by the Ficoll-Isopaque method. The resulting line, KR-4, was found to be resistant to 0.5 mM ouabain 5 mo after mutagenesis.
Cell Fusion and Hybrid Selection. Prior to fusion, the SGuaR, OuaR human B-LCL KR-4 was grown in the same medium as cryopreserved B6, supplemented with 30 ,Ag of 6-thioguanine per ml and 0.1 mM ouabain to counterselect possible revertants. For fusion, 107 B6 cells and 107 KR-4 cells were washed in serum-free medium and then mixed in 50-ml tubes (Falcon) . After centrifugation at 150 X g at room temperature, cells were fused essentially as described by Kohler and Milstein (12) by using 45% (wt/vol) polyethylene glycol (Mr, 4 (10) . For detection of class-specific Ig, microtiter wells were coated with 10 Ag ofthe F(ab')2 fragment of goat anti-human Ig per ml (Cappel Laboratories, Cochranville, PA), and antibodies that bound were detected with heavy (H) chain-specific, goat anti-human IgG or anti-IgM conjugated to alkaline phosphatase (Sigma).
Surface Ig and Human Histocompatibility Antigen (HLA) Typing. Cells were stained by immunofluorescence with class specific reagents as described (10) . The HLA-A and -B antigens were assayed by the Immunology Laboratory of the Kingston General Hospital by a microcytotoxicity method as described by Terasaki and McClelland (14) .
Cloning (16) . The immune complexes were resuspended in Laemmli buffer, analyzed on 12.5% NaDodSO4/polyacrylamide gels (17) , and subjected to fluorography for 4 days at -70°C. Chromatographically purified human IgM and IgG (Cappel Laboratories) were used as markers. In general, all hybrids and KR-4 exhibited weak immunofluorescence (Leitz UV microscope), whereas B6 was strongly fluorescent. * Total secreted Ig was determined in an ELISA assay with F(ab')2 goat anti-human Ig in the solid phase. § Shown in pug/ml. Specific antibody was determined in an ELISA with TT in the solid phase. Cells were at the steady state or declining phase of growth (day 9). 1Shown in ug per i05 cells, determined from experiments described in Fig. 3 during logarithmic (1982) from an analysis of HLA antigens expressed on parental cells and hybridomas. As expected, several HLA haplotypes were codominantly expressed in the hybrids (Table 2 ). In addition, KR-4 was found to secrete IgG and B6 secreted IgM exclusively whereas KR4-B6 hybrids produced both IgM and IgG, in agreement with the class of Ig detected on the cell surfaces by immunofluorescence (Table 2) .
Proteins produced by each cell line were biosynthetically labeled with [U5S]methionine, and the Igs were precipitated with class-specific rabbit anti-human Ig and Staphylococcus aureus protein.
Precipitates were electrophoresed in 12.5% NaDodSO4/polyacrylamide gels, and, as shown in Fig. 2 , a representative KR-4-B6 hybrid clone secreted high amounts of both Au and y chains from each parent, as well as light (L) chain after 24 hr. The KR-4 parent secreted low levels of y and L chains, whereas the B6 parent secreted a large amount of A chain and little L chain. The coexpression of Ig H and L chains characteristic ofeach parental cell line further substantiates the hybrid nature of the selected fusion products. Antibody Production. Fifty-four out of 56 hybrids between KR-4 and B6 were positive when screened by ELISA for production of anti-TT antibody. The four most positive hybrids were subsequently cloned by limiting dilution. Out of395 subclones, 23 did not produce detectable amounts of anti-TT antibodies, the majority produced varying levels, and seven secreted high levels (3-6 /Lg/ml) ofIgM K chain anti-TT antibody.
The mean cloning efficiency of three hybrids (64%) was at least 2-fold higher than the cloning efficiency of the B6 line ( Table  2) .
Three of these hybridoma clones selected for further studies produced 3, 4, and 6 ,ug per ml, respectively, of anti-TT antibody at the end of a growth period of 9 days (Fig. 3) , starting from an inoculum of 2 x 104-cells per ml. The B6 parent pro- duced 75-87.5% less anti-TT antibody and KR-4 produced none (level of detection, 1 ng/ml). The rate of antibody production during the logarithmic phase ofcell proliferation was 13-to 18-fold higher in the hybrids than in the B6 parental line when a mode ofrepresentation described by Monod et aL was used (21) . The rate of antibody production was not constant but exponentially increased for all cell lines tested (Fig. 3) . This is not unexpected because production of antibody in the supernatant is the terminal stage of a sequential process that involves synthesis, assembly, and secretion, all ofthem being programmed and coordinated during the cell cycle. The B6 parent was unusual in that higher titers were detected during the declining phase of cell growth, possibly due to the release of intracellular and membrane Ig from dying cells.
Our original EBV-transformed line, B6, produced =700 ng of anti-TT .antibody per ml during continuous culture for 8 mo. When assayed again after 10 mo ofculture-, the level ofanti-TT production had fallen to <10 ng/ml possibly because of the declining L chain synthesis, which was apparent at 8 mo ofculture (Fig. .3) . Fusion of KR-4 with B6 from 8-mo cultures "rescued" anti-lT production, and three clones designated 20.42, 8.10, and 10.3 maintained constant levels ofanti-TT production (3,000-6,000 ng/ml) throughout 7 mo ofcontinuous culture to the present time.
DISCUSSION
The results presented here demonstrate that relatively high amounts of specific monoclonal antibody can be rescued from In order to allow adequate selection of hybrids, it was necessary to introduce an OuaR marker into an already established SGuaR B-LCL because the EBV-infected lymphocytes used for fusion are already immortalized and could not be counterselected otherwise. SGuaR B-LCL cells were mutated by lowlevel y-irradiation, selected for OuaR, and fused with an EBVtransformed cell line (B6) that itself produced only small amounts of anti-TT antibody. Because of the dominance of the QuaR marker and the recessiveness of the SGuaR marker in the parental B-LCL (KR-4), only hybrid' cells derived from the fusion of KR-4 and B6 could survive selection in HAT medium containing ouabain. The hybrid nature of the clones was confirmed by karyotype analysis, HLA typing, and Ig isotype expression. The hybridomas produced 4-to 8-fold more anti-TT antibody per 106 cells than the B6 parent did, whereas the rate ofantibody synthesis and secretion was 13-to 18-fold higher in the hybrids. Biosynthetic labeling of proteins followed by NaDodSO4/polyacrylamide electrophoresis of immunoprecipitates revealed that hybrids synthesized both p. and y chains from the parental lines as well as K L chains. The EBV-transformed B6 parental line synthesized very little L chain in comparison to 1L chain, a finding that may explain the declining anti-TT titer observed during prolonged proliferation. It is noteworthy that anti-TT production in hybridomas remained stable for 7 mo up to the present time, whereas anti-lT production in nonfused B6 cells ceased after 10 mo of continuous culture.
The findings here support the experimental data of Levy and Dilley (6) , who demonstrated that human neoplastic B cells, which do not normally secrete Ig, can be induced to secrete large amounts ofIg, when hybridized to a mouse myeloma line. Others have shown human Ig secretion by hybrids between mouse myeloma and normal human peripheral blood lymphocytes (22) . We have fused an EBV-transformed cell line with a non-Ig-secreting mouse myleoma (23) , and the established hybridoma clones produced anti-TT antibody. It is known, however, that human chromosomes 14 (H chain) and 22 (A L chain) are preferentially retained in mouse-human hybrids, whereas chromosome 2 (K L chain) is preferentially lost (24, 25) . For this reason, human-human hybrids are to be preferred because intraspecific crosses are more stable. It is remarkable that, in our initial study, only 3.5% of the clones were found to be nonsecretors. The karyotype analysis also indicated that chromosome secretion was very limited, and, in several instances, a chromosome mode close to the tetraploid number was found.
Another potential advantage ofthe technique described here is that EBV behaves as a polyclonal activator of B cells (26) and can be used to promote the expansion of rare antigen-specific B cells in vitro prior to fusion. We also have found that EBVtransformed human B cells are 25-fold more susceptible to hybridization with KR-4 compared with fresh, nontransformed B lymphocytes.
In summary, we have shown that fusion of an OuaR, SGuaR human B-LCL with EBV-transformed cell lines may be the method of choice for the production of human monoclonal antibody because (i) the resulting hybrids are stable (27 mo), have a higher cloning efficiency, and produce antibody at a rate at least one order of magnitude higher than EBV-transformed parental cells; (ii) there is little restriction as to the type ofantibody produced because the antigen-specificity ofthe molecule is determined initially by the choice of vaccinated human donors; (iii) rare antigen-specific B cells in the peripheral blood could conceivably be expanded by EBV transformation prior to fusion, and (iv) EBV-transformed lymphocytes fuse preferentially to KR4 cells compared to nontransformed B cells.
